" "

OXBRYTA RECALL ALERT

We are Pursuing Cases of Illness or Death Due to the Recalled Oxbryta Sickle Cell Drug.

Legal cases are being started on behalf of people taking Oxbryta (voxelotor) to treat sickle cell anemia. Potential clients may be people suffering from an increase in vaso-occlusion crisis events or the death of a loved one. These are the main Oxbryta side effects leading to its recall.

If you used Oxbryta and suffered either of these injuries, reach out to us today. We can get you the justice and any financial compensation you deserve, by helping you explore your legal options.

FDA Announces
OXBRYTA DRUG RECALL

On September 26, 2024, the U.S. Food & Drug Administration (FDA) announced that manufacturer Pfizer, Inc., issued a voluntary recall of Oxbryta due to safety concerns. (1) 

Oxbryta was approved by the FDA, through an expedited process, in 2019 for adults and children 12 years and up with sickle cell disease. In 2021, FDA granted accelerated approval for patients who are 4 to 11 years old. (2) 

“Pfizer knows this is a defective drug. That is why they have pulled  it from the market. The company rushed their drug through the FDA approval process to get it on the market without adequate study. They should be held accountable for the harm their product has inflicted on sickle cell patients. No medication — intended to help people — should cause more pain and suffering to those already suffering enough,” says our co-counsel’s distinguished defective medicine litigator.

Risks of Vaso-Occlusion and Death from Oxbryta

In making the announcement, Pfizer said, “recent data indicate the benefit of Oxbryta does not outweigh the risks for the sickle cell patient population.” Findings by Pfizer showed a higher rate of vaso-occlusion crisis and more deaths among patients taking the drug than those taking a placebo. (3)

Patients taking Oxbryta should consult their doctors immediately regarding whether to stop taking their medication or not.

Symptoms of
Vaso-Occlusion Crisis

The primary symptom of vaso-occlusion crisis is moderate to severe pain, with varying intensity and frequency. Young children may have swelling of hands and feet, along with pain. (4) 

Pain can be in any part of your body but is often in the extremities, back, and chest. Patients may or may not have fever. (5)

Complications of
Sickle Cell Disease

The  terrible complications of sickle cell disease are numerous. Some can affect the entire body. Among these are: vaso-occlusion, chronic pain, vitamin deficiency, delayed growth and puberty, infections, joint problems, blood clots, and pregnancy issues. (6) 

Complications affecting specific parts of your body include acute chest syndrome (when lungs are deprived of oxygen), enlarged spleen, eye problems, gallstones, heart problems, kidney problems, leg ulcers, liver problems, priapism, stroke, and silent brain injury (damage to the brain without outward signs or symptoms of stroke). (7)

Sickle Cell
Disease

Sickle cell disease is a blood disorder that distorts the shape of red blood cells, impeding the delivery of oxygen throughout the body. Vaso-occlusion is “severe pain caused by sickled red blood cells blocking blood flow and oxygen delivery to tissues.” (8)

Sickle cell anemia affects the hemoglobin in red blood cells. Hemoglobin is  a protein that allows red blood cells to carry oxygen. Normal red blood cells are disc-shaped and flexible, allowing them to move easily through blood vessels. Sickle cell anemia causes these cells to become misshaped, like crescents or sickles. Sickling causes pain and impedes oxygen delivery to the body. Oxbryta  was supposed to prevent the sickling of red blood cells. (9)

Reach Out to us for
Your Oxbryta Legal Case

Sickle cell disease is a blood disorder that distorts the shape of red blood cells, impeding the delivery of oxygen throughout the body. Vaso-occlusion is “severe pain caused by sickled red blood cells blocking blood flow and oxygen delivery to tissues.” (8)

We are investigating cases of sickle cell patients harmed by the medication Oxbryta (voxelotor). We encourage you to reach out to us if you have experienced an additional vaso-occlusion crisis after taking this medication, or if a loved one has died.

Please contact us by calling (855)769-1766. We offer a free initial consultation and respond quickly to all inquiries.

We Fight For You

Our co-counsel team of defective drug attorneys are always ready to take on drug companies, anywhere in the country, whose products harm vulnerable people. We have been holding large companies and manufacturers accountable for over four decades. We can assist you in considering all of your legal options. 

A lawsuit can be filed on your behalf (pursuant to several key criteria), so that you may obtain compensation for your injuries. We understand the suffering you have endured, and we fight to ensure that you get the optimal compensation the law allows in your case.

Our co-counsel has a solid history of winning cases for clients. We are ready to take on this fight for you. 

We Fight For You

Our co-counsel team of defective drug attorneys are always ready to take on drug companies, anywhere in the country, whose products harm vulnerable people. We have been holding large companies and manufacturers accountable for over four decades. We can assist you in considering all of your legal options. 

A lawsuit can be filed on your behalf (pursuant to several key criteria), so that you may obtain compensation for your injuries. We understand the suffering you have endured, and we fight to ensure that you get the optimal compensation the law allows in your case.

Our co-counsel has a solid history of winning cases for clients. We are ready to take on this fight for you. 

Sources:

  1. U.S. Food & Drug Administration. (2024, September 26). FDA  is alerting patients and health care professionals about the voluntary withdrawal of Oxbryta from the market due to safety concerns. Retrieved from https://www.fda.gov/drugs/drug-safety-and-availability/fda-alerting-patients-and-health-care-professionals-about-voluntary-withdrawal-oxbryta-market-due
  2. Ibid.
  3. Ibid.
  4. Borhade, M.B., et al.(2024). Sickle Cell Crisis. Retrieved from https://www.ncbi.nlm.nih.gov/books/NBK526064/
  5. Ibid.
  1. National Institutes of Health. National Heart, Lung, and Blood Institute. (2024, August 22). Sickle Cell Disease. How Sickle Cell Disease. May Affect Your Health. Retrieved from https://www.nhlbi.nih.gov/health/sickle-cell-disease/health-effects
  2. Ibid.
  3. U.S. Food & Drug Administration. (2024, September 26). FDA  is alerting patients and health care professionals about the voluntary withdrawal of Oxbryta from the market due to safety concerns. Retrieved from https://www.fda.gov/drugs/drug-safety-and-availability/fda-alerting-patients-and-health-care-professionals-about-voluntary-withdrawal-oxbryta-market-due
  4. National Institutes of Health. National Heart, Lung, and Blood Institute. (2024, September 30). Sickle Cell Disease. What Is Sickle Cell Disease? Retrieved from https://www.nhlbi.nih.gov/health/sickle-cell-disease

Call (855)769-1766

© 2025 SARABETH KUFELD, ESQ. ATTORNEY ADVERTISING. PRIOR RESULTS DO NOT GUARANTEE A SIMILAR OUTCOME. OFFICE MAILING ADDRESS: SUITE 224, 16 MIDDLE NECK ROAD, GREAT NECK, NY 11021 DO NOT DISCONTINUE TAKING PRESCRIBED MEDICATIONS UNLESS YOU FIRST CONSULT YOUR DOCTOR. YOU ARE NOT CONSIDERED A CLIENT UNTIL YOU HAVE SIGNED A RETAINER AGREEMENT.

OUR CO-COUNSEL IN THIS LITIGATION IS ONE OF THE USA’S LARGEST, MOST EXPERIENCED AND MOST PROLIFIC (IN TERMS OF TOTAL VERDICTS AND SETTLEMENTS ACHIEVED) MASS TORT LITIGATION FIRMS, WEITZ & LUXENBERG P.C.